PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $71.99M
• Dividend Yield: N/A
• Average Volume (3M): 463.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: N/A
• EPS Growth: -58.47%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 53,329,390
• 10 Day Avg. Volume: 318,832
• 30 Day Avg. Volume: 463,553
• PEG Ratio: -0.03
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.89
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -425.25
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $4.00
• Price Target Upside: 257.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.37
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.50 ▲(33.93% Upside)
• Action: Reiterated Date: 04/15/26
• Date: Action: Reiterated 04/15/26

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising cash burn that may require future financing), partially offset by low leverage on the balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation offers limited insight due to a negative P/E and no dividend yield.

Positive Factors

Low Leverage

Very low debt reduces fixed financial obligations and interest burden, preserving optionality for funding R&D or pursuing partnerships. Over the medium term this structural conservatism lowers bankruptcy risk and increases flexibility in choosing financing paths as programs advance.

Negative Factors

Persistent Cash Burn

Consistent negative operating and free cash flow, with rising burn in 2025, creates a durable funding gap that will likely require new capital or partnerships. This ongoing consumption increases dilution risk and pressures management to secure financing before key value inflection points.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that co...

Read more

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that co...

How the Company Makes Money

PMV Pharmaceuticals is a clinical-stage biopharmaceutical company and, as such, it typically does not generate recurring product sales revenue because it does not have broadly marketed, commercial-stage drugs. Its potential and/or historical sourc...

Read more

PMV Pharmaceuticals is a clinical-stage biopharmaceutical company and, as such, it typically does not generate recurring product sales revenue because it does not have broadly marketed, commercial-stage drugs. Its potential and/or historical sourc...

PMV Pharmaceuticals Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-133.00K	-1.14M	-1.26M	-650.00K	-1.28M
EBITDA	-86.21M	-73.67M	-67.70M	-72.68M	-56.54M
Net Income	-77.74M	-58.71M	-68.96M	-73.32M	-57.85M
Balance Sheet
Total Assets	116.56M	191.29M	252.15M	270.31M	331.57M
Cash, Cash Equivalents and Short-Term Investments	112.94M	169.45M	203.06M	241.05M	297.16M
Total Debt	838.00K	1.19M	13.29M	13.98M	11.19M
Total Liabilities	11.85M	15.21M	26.46M	24.28M	23.01M
Stockholders Equity	104.71M	176.08M	225.69M	246.03M	308.56M
Cash Flow
Free Cash Flow	-73.61M	-51.94M	-56.62M	-71.74M	-47.92M
Operating Cash Flow	-73.58M	-51.28M	-55.66M	-63.76M	-46.57M
Investing Cash Flow	70.17M	53.35M	-50.55M	-1.37M	-143.58M
Financing Cash Flow	505.00K	313.00K	35.58M	958.00K	2.02M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Positive. The current price of 1.12 is below the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.33, and below the 200-day MA of 1.33, indicating a bullish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 58.76 is Neutral, neither overbought nor oversold. The STOCH value of 76.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	55 Neutral	$275.32M	-2.24	-129.98%	―	250.00%	15.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PMVP	48 Neutral	$71.99M	-0.84	-59.07%	―	―	-58.47%
XFOR	48 Neutral	$375.50M	-2.14	-115.27%	―	2925.73%	-294.29%
GANX	46 Neutral	$78.99M	-5.27	-237.54%	―	―	42.29%
ABVC	45 Neutral	$35.11M	-6.26	-88.89%	―	56.52%	75.22%